Jazz Pharmaceuticals (JAZZ) PT Raised at RBC Capital on 'Meaningful Upside' Potential
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $151.00 (from $145.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
